Pain-indicated buprenorphine prescribing in the United States, 2017–2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study
Background Buprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients. Methods Longitudinal ecological analysis of 2017-2025 prescription claims for 867,591 unique adults receiving transdermal or buccal buprenorphine across 888 three-digit ZIP code areas, with a systematic policy review of the 50 states and District of Columbia. Outcomes were annual recipients of pain-indicated formulations per 100,000 adults, observed and modeled with a hierarchical Bayesian model (95% credible intervals), state policy characteristics, and payer-restricted rates. Results The observed national rate increased from 53.59 to 78.04 recipients per 100,000 adults (45.6%; 4.81% annualized); model-derived average annual growth was 5.04% (95% credible interval, 2.88%-7.28%). The policy review identified distinct guidance, coverage, oversight, and educational approaches. Annualized growth was 25.43% in Minnesota, 13.50% in Colorado, 6.29% in North Carolina, 3.35% in Virginia, 2.99% in California, 0.63% in West Virginia, 0.50% in Oregon, and −2.96% in Mississippi. Identifiable-Medicaid prescribing grew 3.10% annualized nationally versus 4.81% for all payers and increased in Colorado and Minnesota, but declined in Virginia and North Carolina, where plan coding and managed-care transitions limited Medicaid identification. Conclusions Prescribing increased nationally but varied substantially across states with different policy approaches, and Medicaid-restricted patterns did not consistently mirror all-payer trends. Policy content, timing, and payer reach warrant evaluation; however, these ecological comparisons do not establish causation.
Authors
- Cara McDonnell (ORCID: https://orcid.org/0000-0001-5035-3582)
- Robert W. Hurley (ORCID: https://orcid.org/0000-0001-6591-9390)
- Meredith C B Adams (ORCID: https://orcid.org/0000-0002-3969-4279)
- David Kline (ORCID: https://orcid.org/0000-0001-6183-3303)
- Jae C Yong
Institutions
- Wake Forest University Health Sciences (US)
- Wake Forest University (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.12.26367897
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- preprint